The agreement between the United Kingdom (UK) and China pledges new areas of cooperation, for example an exchange of learning from the accelerated access review (AAR) and how to effectively regulate the trading of medicines online.
The Medicines and Healthcare products Regulatory Agency (MHRA) have signed a memorandum of understanding with the China Food and Drug Administration (CFDA). The signing expands on a previous memorandum of understanding signed in 2014, which focussed on the exchange of safety information on medicines and medical devices to protect patients in the UK, China, and around the world.
The MHRA states that “China is a world leader in the market for raw materials for the pharmaceutical industry and closer collaboration with MHRA will support the promotion of innovation, good practice, and protect UK patients.”
The MHRA’s aim is to formalise international relationships and help strengthen regulatory systems to protect public health worldwide.
To read more about the signed memorandum between the UK and China, please click here.